<DOC>
	<DOC>NCT00723957</DOC>
	<brief_summary>The purpose of this study is to determine whether progression-free survival with ixabepilone is superior to that achieved with paclitaxel plus carboplatin in participants with advanced nonsmall-cell lung cancer and beta III (βIII)-tubulin-positive tumors.</brief_summary>
	<brief_title>A Randomized Phase 2 Study of Ixabepilone Plus Carboplatin and Paclitaxel Plus Carboplatin in Advanced Nonsmall-Cell Lung Cancer</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Epothilones</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<criteria>Histologically confirmed nonsmall cell lung cancer (NSCLC)(squamous cell, adenocarcinoma, large cell, or bronchoalveolar carcinoma) Stage IIIB NSCLC with pleural effusion, Stage IV NSCLC, or recurrent disease following surgery with or without radiation therapy Available paraffinembedded tissue to measure the expression levels of βIII tubulin Disease measurable by Response Evaluation Criteria in Solid Tumors, with at least 1 target lesion situated outside any previous radiotherapy field Karnofsky performance status of 70100 Life expectancy of at least 3 months Men and women, ages 18 years and older Uncontrolled brain metastases Peripheral neuropathy greater than Grade 1 Fewer than 4 weeks from prior radiation therapy or locoregional surgeries to randomization date (less than 1 week from focal/palliative radiotherapy or minor surgery) Any concurrent malignancy other than nonmelanoma skin cancer or carcinoma in situ of the cervix Known HIVpositive status Absolute neutrophil count lower than 1500 cells mm^3 Total bilirubin level higher than upper limit of normal (ULN) as defined by the institution (with the exception of elevation due to Gilbert's syndrome) Aspartate transaminase or alanine transaminase level higher than 2.5*ULN Serum creatine level of 1.5 mg/dL or higher Renal function with a creatinine clearance of less than 50 mL/min (as calculated with the Cockcroft and Gault equation) Any prior antineoplastic systemic regimens.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2016</verification_date>
</DOC>